Eli Lilly's weight-loss drug helps nearly 99% of patients remain diabetes-free
Eli Lilly said on Wednesday its weight-loss drug helped nearly 99% of patients remain diabetes-free after three years of weekly injections. The results suggest that tirzepatide - the active ingredient in Lilly's diabetes drug Mounjaro and weight-loss treatment Zepbound - could prevent one new case of diabetes for every nine patients treated.
99% Of Mounjaro/Zepbound Patients Remained Diabetes-Free Even At 3 Years, Eli Lilly's Detailed Phase 3 Data Shows
Eli Lilly's Phase 3 study shows tirzepatide significantly cuts type 2 diabetes risk and supports 22.9% average weight loss in adults over three years.
Eli Lilly Say Most Tirzepatide Users Remained Diabetes-Free at 176 Weeks
Eli Lilly said new results from a Phase 3 study of its tirzepatide showed weekly injections in adults with pre-diabetes and obesity or overweight resulted in sustained weight loss, with nearly 99% remaining diabetes-free at 176 weeks.
Lilly reports trial results of tirzepatide for treating obesity and pre-diabetes
Eli Lilly has reported comprehensive outcomes from the SURMOUNT-1 study of tirzepatide (Zepbound and Mounjaro) for treating pre-diabetic and obese individuals. Spanning 176 weeks of treatment, the Phase III trial evaluated the efficacy and safety of tirzepatide in adults without type 2 diabetes (T2D) who were either obese or overweight with complications such as cardiovascular disease,
Hosted on MSN7d
Zepbound's Weight Loss, Cardiometabolic Benefits Hold Up at 3 Years
SAN ANTONIO -- Patients with overweight or obesity lost an average one-fifth of their body weight with the highest dose of ...
Forbes11mon
Discontinuing Obesity Drug Zepbound Leads To Weight Rebound: Why This Matters To Insurers
Patients on the weight-loss drug Zepbound regained weight ... In the SURMOUNT-4 study, a similar cohort of trial participants on Zepbound also achieved significant weight reduction.
What are your questions about weight loss drugs?
Weight loss and diabetes drugs Ozempic, Wegovy, Mounjaro and Zepbound are seen as game-changers for obesity and weight ...
Weight Loss Injections: What You Need to Know, From Costs to Alternatives
Weight loss can be a challenge, even for those who eat healthily and exercise regularly. But injectable type 2 diabetes ...
Forbes11mon
FDA Approved A New Weight Loss Drug Zepbound. Here’s What To Know And Expect
People with obesity who took the highest dose of the drug lost 21 percent of their total body weight, according to a randomized-controlled trial ... using Zepbound for short-term weight loss ...
Fast Company1mon
Why Ozempic, Zepbound, and other weight-loss drug dupes carry risks
To combat these alternative sellers, pharmaceutical company Eli Lilly began offering an alternative version of its brand-name Zepbound product for weight loss in September 2024. Instead of its ...
Time on MSN23d
Weight-Loss Drugs May Help Alcohol and Opioid Addiction
Weight-loss drugs like Wegovy and Zepbound are transforming the health of millions of ... association between the ...
WPTV-TV11mon
New weight-loss drug Zepbound now available in US pharmacies
It's similar to semaglutide injections known as Ozempic and Wegovy, which are also prescribed for weight loss. In clinical trials, the Food and Drug Administration said Zepbound was found to ...
Amgen stock falls as analysts mull over weight loss drug's bone density data
Analysts cited data from a phase one study showing the highest dose of Amgen’s MariTide was linked to roughly 4% loss of bone ...